drugset / Trial / NCT03216408

Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines

NCT03216408

Phase 3 Completed 504 enrolled Medy-Tox
RandomizedParallel-groupDouble-blindTreatment

Summary

This clinical study evaluates the efficacy and safety of Neuronox compared with Botox in adults with moderate to severe glabellar lines.

Timeline

Start
2016-03-30
Primary completion
2016-11-10
Completion
2017-03-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic
Subject Neuronox Protein / enzyme biologic

Indications

No indication recorded.